US manager eyes strong Nordic interest for its new biotech 2.0 fund

BNY Mellon Investment Management has launched a fund seeking to benefit from the growing gene therapy treatment market. The asset manager's director of Nordic distribution Viktoria von Kunow has high regional hopes for the new thematic fund.

BNY Mellon Investment Management's director Nordic Distribution Viktoria von Kunow | Photo: PR / BNY Mellon Investment Management

US-based BNY Mellon Investment Management is launching an actively managed thematic fund which will invest in companies that are developing gene therapy, gene editing and gene modulation treatments.

The USD 2.2trn asset manager notes a demand for thematic funds in the Nordics, especially in the context of responsibility, director of Nordic distribution Viktoria von Kunow says.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

ATP's managed assets maintained growth in Q3

A positive result from investments and a negative hedging portfolio outcome are the main takeaways from ATP's Q3 report, which reports that total managed assets have increased, and the bonus rate has also swelled further.

Velliv divests coal and tar sands

Neither coal nor oil extracted from tar sands will be be found in Velliv's portfolio now that the company has decided to completely exclude companies associated with those activites.

Further reading

Related articles

Trial banner

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch